Company intelligence / Profile preview

BioSight

Airport City, Central District, Israelbiosight-pharma.com ↗

Ownership: Private
Development stage: Phase 3

Overview

BioSight’s lead product, BST‑236 (aspacytarabine), is an anti-metabolite chemotherapy agent designed to enable high-dose chemotherapy with reduced systemic toxicity. As of the latest reports before its merger, BST‑236 was in a Phase 2b trial as a first-line treatment for AML in patients unfit for intensive chemotherapy. The company aimed to expand into additional indications within hematologic cancers.

Therapeutic areas: OncologyHematology
Modalities: Small molecules (notably anti-metabolites)
Industry: Biotech

Drug pipeline

1 asset

BS-003

Preclinical

Beyond the preview

Go deeper on BioSight.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioSight.

Explore the full profile